Compare Bristol-Myers Squibb Co (BMY) vs Figs Inc (FIGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Figs Inc — how do they compare? Bristol-Myers Squibb Co trades at $59.02 (market cap $116.30B), while Figs Inc trades at $10.16 (market cap $1.62B). The key difference: Bristol-Myers Squibb Co is far larger — about 71.8× Figs Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Figs Inc pays none. Which is the better fit depends on your goals.
| BMY | FIGS | |
|---|---|---|
Market Cap | $116.30B | $1.62B |
Sector | Health | Consumer Cyclical |
52-Week High | $62.37 | $17.12 |
52-Week Low | $42.60 | $5.81 |
Enterprise Value | $152.24B | $1.41B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
FIGS trades at $10.00, down 0.4% on the day, with a bearish technical signal from moving averages but recent earnings beats. The company reported Q1 2026 revenue growth of 28% and raised full-year guidance, though net cash flow remains negative. Analyst consensus is a Buy with a $19.50 price target, implying significant upside from current levels.
The outlook is mixed: strong fundamentals and growth prospects support the bull case, but valuation is rich at a P/E of 45.45, and margin pressures from tariffs and spending pose risks. The stock's performance hinges on execution of global expansion and cost management amid competitive and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →
